World's Best Scientists 2026 revealed!
Pierfrancesco Tassone

Pierfrancesco Tassone

D-Index & Metrics

Medicine

D-Index
86
Citations
22372
World Ranking
14293
National Ranking
548

Pierfrancesco Tassone publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Pierfrancesco Tassone sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 486 publications — 56th percentile

56% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Pierfrancesco Tassone D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Pierfrancesco Tassone sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Pierfrancesco Tassone is affiliated with Magna Graecia University in Italy. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a significant focus on Molecular Biology and Oncology. The scientist's work encompasses various subfields including Cancer Research, Immunology, and Pulmonary and Respiratory Medicine.

The main topics of their research include:

  • Cancer Immunotherapy and Biomarkers
  • Cancer-related molecular mechanisms research
  • Multiple Myeloma Research and Treatments
  • CAR-T cell therapy research
  • MicroRNA in disease regulation
  • RNA Research and Splicing
  • RNA Interference and Gene Delivery

Among recent papers published with their involvement are:

  • "Non-coding RNAs in cancer: platforms and strategies for investigating the genomic "dark matter"" (2020), published in Journal of Experimental & Clinical Cancer Research
  • "Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial" (2020), published in The Lancet Respiratory Medicine
  • "miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review" (2022), published in Molecular Therapy - Nucleic Acids
  • "Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease" (2020), published in Scientific Reports
  • "Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer's Achilles' Heel" (2021), published in Cancers

The scientist has published frequently in several academic venues, including:

  • Cancers
  • Blood
  • Journal of Experimental & Clinical Cancer Research
  • Molecular Therapy - Nucleic Acids
  • Journal of Clinical Oncology

Collaboration has been an important aspect of their work, especially with frequent co-authors including:

  • Maria Teresa Di Martino
  • Daniele Caracciolo
  • Pierosandro Tagliaferri
  • Mariamena Arbitrio
  • Francesca Scionti

Best Publications

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

    Arlene Chan;Suzette Delaloge;Frankie A Holmes;Beverly Moy

  • Mir-34: A New Weapon Against Cancer?

    Gabriella Misso;Maria Teresa Di Martino;Giuseppe De Rosa;Ammad Ahmad Farooqi

  • Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

    Mariateresa Fulciniti;Pierfrancesco Tassone;Teru Hideshima;Sonia Vallet

  • BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

    P Tassone;P Tassone;P Tagliaferri;A Perricelli;S Blotta

  • HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.

    Ennio Carbone;Paola Neri;Maria Mesuraca;Mariateresa T. Fulciniti

  • Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

    Laurence Catley;Ellen Weisberg;Ellen Weisberg;Tanyel Kiziltepe;Tanyel Kiziltepe;Yu-Tzu Tai;Yu-Tzu Tai

  • Dysfunctional T regulatory cells in multiple myeloma

    Rao H. Prabhala;Paola Neri;Jooeun E. Bae;Pierfrancesco Tassone

  • MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches.

    Nicola Amodio;Lavinia Raimondi;Giada Juli;Maria Angelica Stamato

  • Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

    Maria T. Di Martino;Emanuela Leone;Nicola Amodio;Umberto Foresta

  • Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.

    Pierpaolo Correale;Maria Saveria Rotundo;Maria Teresa Del Vecchio;Cinzia Remondo

  • Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth

    Emanuela Leone;Eugenio Morelli;Maria T. Di Martino;Nicola Amodio

  • Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.

    Yi-Long Wu;Ying Cheng;Jianying Zhou;Shun Lu

  • Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.

    Nicola Amodio;Maria Angelica Stamato;Giada Juli;Eugenio Morelli

  • miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease.

    Marco Rossi;Maria Rita Pitari;Nicola Amodio;Maria Teresa Di Martino

  • Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines.

    P Tassone;S Forciniti;E Galea;G Morrone

  • Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.

    P Tassone;P Tagliaferri;C Viscomi;C Palmieri

  • miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

    N Amodio;M T Di Martino;U Foresta;E Leone

  • Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.

    Pierfrancesco Tassone;Victor S. Goldmacher;Paola Neri;Antonella Gozzini

  • B563 Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic Agent for Multiple Myeloma

    M Fulciniti;S Vallet;S Ettenberg;X Shen

Frequent Co-Authors

Nikhil C. Munshi
Nikhil C. Munshi Harvard University
Salvatore Venuta
Salvatore Venuta Magna Graecia University
Antonino Neri
Antonino Neri University of Milan
Michele Caraglia
Michele Caraglia University of Campania "Luigi Vanvitelli"
Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Teru Hideshima
Teru Hideshima Harvard University
Dharminder Chauhan
Dharminder Chauhan Harvard University
Yu-Tzu Tai
Yu-Tzu Tai Harvard University
Luca Agnelli
Luca Agnelli University of Milan
Mario Cannataro
Mario Cannataro Magna Graecia University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees offers flexible options for advancing your career in medicine, healthcare, or administration. Many students aiming for medical professions consider accelerated msn psychiatric np programs to quickly transition into high-demand mental health nurse practitioner roles. These programs often provide intensive coursework with the convenience of online learning.

For those interested in non-clinical healthcare careers, a healthcare administration degree cost is a key factor to weigh. Comparing tuition rates and scholarship opportunities is essential, as costs can vary widely between institutions.

Aspiring leaders can also look for the cheapest online mha programs to earn a Master’s in Healthcare Administration without accumulating significant debt. Budget-friendly options make it possible to access high-quality education and unlock leadership roles in hospitals, clinics, or health systems.

Finally, nurses aiming for advanced practice can seek the least expensive dnp programs to achieve a Doctor of Nursing Practice degree online. Affordable online DNP programs help professionals reach the highest level of nursing expertise while maintaining their current jobs.

Best Scientists Citing Pierfrancesco Tassone

Trending Scientists

Recently Published Articles